Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II randomized open-label crossover trial of JW2202 dry powder inhaler in COPD
CTR20242119Phase 2Completed
- Sponsor
- Shandong Jianwei Pharmaceutical
- Start
- Jun 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of indacaterol acetate + glycopyrronium bromide + mometasone furoate in chronic obstructive pulmonary disease (COPD), sponsored by Shandong Jianwei Pharmaceutical. Started Jun 2024; status: completed.
02
Drugs
indacaterol acetate + glycopyrronium bromide + mometasone furoate
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20242119.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242119.